Table 2.
Objective response by mRECIST predicts overall survival: retrospective analysis
| Study, year | Agents (study design) | ORR (mRECIST), % (n/N) | Median OS, months |
HR (95% CI) | p value | |
|---|---|---|---|---|---|---|
| responder (CR + PR) | nonresponder (SD + PD) | |||||
| Ronot [4], 2012 | sorafenib (retrospective) | 28.1 (18/64) | 25.5 | 13.3 (SD) 5.7 (PD) |
N/A | <0.001 |
| Arizumi [5], 2014 | sorafenib (retrospective) | 22.8 (36/158) | 25.4 | 7.3 (PD) 5.7 (short SD) |
N/A | <0.0001 |
| Edeline [6], 2014 | sorafenib (retrospective) | 22.6 (12/53) | 18 | 8 | N/A | 0.013 |
| Takada [7], 2015 | sorafenib (retrospective) | 13.1 (25/191) | 22.0 | 10.0 | N/A | 0.0117 |
ORR, objective response rate; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.